## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	(oco ao many emocre	,,	
Sheet	1	of	2

C	omplete if Known	
Application Number	10/534,985	
Filing Date November 10, 2003		
First Named Inventor Andreas M. ZEIHER		
Art Unit 1641		
Examiner Name	Lisa V. Cook	
Attorney Docket Number	05552.1459-00000	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS						
	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No.	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-4,477,575	10-16-1984	Vogel		
		US-6,333,397	12-25-2001	Katus		

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		WO 01/85796 A2	11-15-2001	Vlaams Interuniversitair Instituut Voor Biotechnologie VZW		
		EP 0045476 A1	02-10-1982	Boehringer Mannheim GmbH		For English language equivalent see U.S. 4,477,575
		EP 0394819 A2	10-31-1990	Boehringer Mannheim GmbH		For English language equivalent see U.S. 6,333,397
		WO 02/09683 A2	02-07-2002	Pharmacia Corporation		
		WO 02/089730 A2	11-14-2002	Millennium Pharmaceuticals, Inc.		
		WO 92/06194 A1	04-16-1992	Consiglio Nazionale Delle Ricerche		

	NONPATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>		
		ANTMAN et al., "Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction," Journal of the American College of Cardiology, vol. 36, pp. 959-969, 2000.			
		BELGORE et al., "Free and Vascular endothelial growth factor (VEGF) complexed soluble receptor Flt-1 in patients with cardiovascular disease," Journal of the American College of Cardiology, abstract no. 1306-185, vol. 37, no. 2, p. 301A, February 2001.			
		BELGORE et al., "Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays," Clinical Science, vol. 100, pp. 567-575, 2001.			
		BIASUCCI et al., "Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease," Italian Heart Journal, vol. 2, pp. 164-171, 2001.			

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

2

Sheet

Complete if Known			
Application Number 10/534,985			
Filing Date November 10, 2003			
First Named Inventor Andreas M. ZEIHER			
Art Unit 1641			
Examiner Name	Lisa V. Cook		
Attorney Docket Number	05552.1459-00000		

NONPATENT LITERATURE DOCUMENTS	
BLANKENBERG et al., "Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina," Journal of the American Heart Association, Circulation, vol. 106, pp. 24-30, 2002.	
BRAUNWALD et al., "ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction–2002," Journal of the American Heart Association, Circulation, vol. 106, pp. 1893-1900, 2002.	
CARMELIET et al., "Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions," Nature Medicine, vol. 7, pp. 575-583, 2001.	
HEESCHEN et al., "Placental Growth Factor: A Novel Serum Marker of Vascular Inflammation the Risk of Patients with Acute Coronary Syndromes," Journal of the American Heart Association, Supplement to Circulation, abstract no. 2152, vol. 108, no. 17, October 28, 2003.	
HEESCHEN et al., "Soluble CD40 Ligand in Acute Coronary Syndromes," The New England Journal of Medicine, vol. 348, no. 12, pp. 1104-11, 2003.	
HEESCHEN et al., "Serum Level of the Antiinflammatory Cytokine Interleukin-10 is an Important Prognostic Determinant in Patients with Acute Coronary Syndromes," Journal of the American Heart Association, Circulation, vol. 107, pp. 2109-2114, 2003.	
LENDERLINK et al., "Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA," European Heart Journal, vol. 24, pp. 77-85, 2003.	
LIBBY et al., "Inflammation and Atherosclerosis," Journal of the American Heart Association, Circulation, vol. 105, pp. 1135-1143, 2002.	
LINDAHL et al., "Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease," The New England Journal of Medicine, vol. 343, no. 16, pp. 1139-1147, 2000.	
LUND et al., "Circulating Pregnancy-Associated Plasma Protein A Predicts Outcome in Patients with Acute Coronary Syndrome but No Troponin I Elevation," Journal of the American Heart Association, Circulation, vol. 108, pp. 1924-1926, 2003.	
LUTTUN et al., "Placental Growth Factor (PIGF) and Its Receptor Flt-1 (VEGFR-1)," Ann. NY. Acad. Sci., vol. 979, pp. 80-93, 2002.	
RIDKER et al., "C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year follow up of 14 719 Initially Healthy American Women," Journal of the American Heart Association, Circulation, vol. 107, pp. 391-397, 2003.	

2

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.